Alzheimer’s treatment thrills investors as doctors debate effect
3 min read . Updated: 06 Dec 2022, 06:54 PM IST
PremiumWall Street wants to know if physicians will prescribe the Eisai and Biogen drug
In a press release in late September announcing that Eisai’s experimental Alzheimer’s drug had significantly slowed progression of the memory-robbing disease, the company’s chief executive officer, Haruo Naito, was anything but circumspect. The results from the late-stage study, he said, “prove the amyloid hypothesis."
×![]()
